GlassScriptPhysician profile
Ashraf A Luqman
NPI 1326153016
$1,723.08
in general payments reported to CMS, 2019-2025
18 companies · $17.38 in 2025
The $17.38 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $248 · 2021: $101 · 2022: $345 · 2023: $343 · 2024: $391 · 2025: $17.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.09 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $377.72 | 2020-2024 | Airsupra, Tezspire, Imfinzi |
| Genzyme Corporation | $195.29 | 2020-2024 | |
| Pulmonx Corporation | $190.10 | 2023-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Regeneron Healthcare Solutions, INC. | $170.64 | 2019-2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $148.71 | 2022-2024 | Acthar |
| Inari Medical, INC. | $137.73 | 2022 | |
| Ethicon INC. | $123.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.15 | 2023-2024 | Glassia |
| Glaxosmithkline, LLC. | $56.46 | 2022-2024 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.48 | 2023 | Stiolto Respimat |
| Philips North America LLC | $37.82 | 2019-2020 | |
| Ceribell, INC. | $32.93 | 2023-2024 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Baxter Healthcare | $18.74 | 2024 | Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Paratek Pharmaceuticals, INC. | $14.69 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $13.22 | 2024 | Prolastin-C Liquid |
| Electromed, INC. | $12.96 | 2023 | Smartvest |
| Sunovion Pharmaceuticals INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Luqman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.